OA10600A - Salts of an anti-migraine indole derivative - Google Patents

Salts of an anti-migraine indole derivative Download PDF

Info

Publication number
OA10600A
OA10600A OA60969A OA60969A OA10600A OA 10600 A OA10600 A OA 10600A OA 60969 A OA60969 A OA 60969A OA 60969 A OA60969 A OA 60969A OA 10600 A OA10600 A OA 10600A
Authority
OA
OAPI
Prior art keywords
compound
formula
daims
suitable solvent
polymorphic form
Prior art date
Application number
OA60969A
Other languages
English (en)
Inventor
Valerie Denise Harding
Ross James Macrae
Ronald James Ogilvie
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10760474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of OA10600A publication Critical patent/OA10600A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
OA60969A 1994-08-27 1997-02-27 Salts of an anti-migraine indole derivative OA10600A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9417310A GB9417310D0 (en) 1994-08-27 1994-08-27 Therapeutic agents

Publications (1)

Publication Number Publication Date
OA10600A true OA10600A (en) 2000-04-06

Family

ID=10760474

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60969A OA10600A (en) 1994-08-27 1997-02-27 Salts of an anti-migraine indole derivative

Country Status (45)

Country Link
US (2) US6110940A (bg)
EP (1) EP0776323B1 (bg)
JP (1) JP2904588B2 (bg)
KR (1) KR100228952B1 (bg)
CN (1) CN1066727C (bg)
AP (1) AP576A (bg)
AT (1) ATE163182T1 (bg)
AU (1) AU691005B2 (bg)
BG (1) BG61840B1 (bg)
BR (1) BRPI9503812B1 (bg)
CA (1) CA2198599C (bg)
CO (1) CO4410334A1 (bg)
CZ (1) CZ287693B6 (bg)
DE (1) DE69501620T2 (bg)
DK (1) DK0776323T3 (bg)
DZ (1) DZ1923A1 (bg)
EG (1) EG23822A (bg)
ES (1) ES2112650T3 (bg)
FI (1) FI113768B (bg)
GB (1) GB9417310D0 (bg)
GR (1) GR3026475T3 (bg)
HR (1) HRP950460B1 (bg)
HU (1) HU227822B1 (bg)
IL (1) IL115013A (bg)
IS (1) IS1850B (bg)
LV (1) LV11800B (bg)
MA (1) MA23650A1 (bg)
MX (1) MX9701538A (bg)
MY (1) MY113733A (bg)
NO (1) NO311297B1 (bg)
NZ (1) NZ288210A (bg)
OA (1) OA10600A (bg)
PE (1) PE41596A1 (bg)
PL (1) PL180867B1 (bg)
RO (1) RO116400B1 (bg)
RU (1) RU2159241C2 (bg)
SA (1) SA95160156B1 (bg)
SI (1) SI9520091B (bg)
SK (1) SK282922B6 (bg)
TN (1) TNSN95092A1 (bg)
TR (1) TR199501061A2 (bg)
UA (1) UA45980C2 (bg)
WO (1) WO1996006842A1 (bg)
YU (1) YU49287B (bg)
ZA (1) ZA957142B (bg)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
SI0999841T1 (bg) * 1997-07-03 2001-12-31 Pfizer
GB9714081D0 (en) * 1997-07-03 1997-09-10 Pfizer Ltd Pharmaceutical compositions
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US20030166704A1 (en) * 2000-12-20 2003-09-04 Pfizer Inc. New process
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
BRPI0409127A (pt) 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
BRPI0715579A2 (pt) * 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
US20080287519A1 (en) * 2007-05-01 2008-11-20 Marioara Mendelovici Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
WO2008150500A1 (en) * 2007-05-29 2008-12-11 Plus Chemicals, S.A. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
US20100285075A1 (en) * 2007-12-17 2010-11-11 Actavis Group Ptc Ehf Novel Hemioxalate Salt of Eletriptan
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
CA2731041C (en) * 2008-08-07 2016-09-06 Biovail Laboratories International Srl Bupropion hydrobromide polymorphs
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) * 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
JP2019502761A (ja) 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
BR9106978A (pt) * 1990-10-15 1993-09-28 Pfizer Derivados de indol
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
BR9206810A (pt) * 1991-11-25 1995-10-31 Pfizer Derivados de indol
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (bg) * 1992-03-05 1996-10-11 Pfizer
CZ281763B6 (cs) * 1992-04-07 1997-01-15 Pfizer Inc. Indolové deriváty představující 5-HT1 agonisty, způsob jejich přípravy, farmaceutické prostředky obsahující tyto látky, jejich použití a meziprodukty postupu přípravy
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
SK278182B6 (en) * 1992-04-10 1996-03-06 Pfizer Acylaminoindole derivatives as 5-ht1 agonists, method of their preparation and pharmaceutical compositions containing these matters their use and semifinished products of preparation proces
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
BR9406481A (pt) * 1993-04-22 1996-01-09 Pfizer Res & Dev Derivados de indol como agonistas do tipo 5-HT1 para utilização na enxaqueca
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
DK0716649T3 (da) * 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater

Also Published As

Publication number Publication date
IS1850B (is) 2003-02-07
DE69501620D1 (de) 1998-03-19
TNSN95092A1 (fr) 1996-02-06
SA95160156B1 (ar) 2005-05-30
BR9503812A (pt) 1996-04-16
NZ288210A (en) 1998-01-26
RO116400B1 (ro) 2001-01-30
LV11800B (en) 1997-10-20
PL180867B1 (pl) 2001-04-30
SK24897A3 (en) 1998-08-05
CA2198599C (en) 2000-06-06
NO970861D0 (no) 1997-02-26
US6380226B1 (en) 2002-04-30
HRP950460A2 (en) 1997-08-31
BG101250A (bg) 1997-09-30
MX9701538A (es) 1997-05-31
BRPI9503812B1 (pt) 2017-04-18
KR970705557A (ko) 1997-10-09
AP576A (en) 1997-03-20
HUT77310A (hu) 1998-03-30
IL115013A (en) 2000-11-21
AU691005B2 (en) 1998-05-07
CO4410334A1 (es) 1997-01-09
RU2159241C2 (ru) 2000-11-20
NO970861L (no) 1997-02-26
LV11800A (lv) 1997-06-20
AU2735295A (en) 1996-03-22
JP2904588B2 (ja) 1999-06-14
ZA957142B (en) 1997-02-25
CZ56397A3 (cs) 1998-05-13
TR199501061A2 (tr) 1996-06-21
MY113733A (en) 2002-05-31
US6110940A (en) 2000-08-29
CZ287693B6 (en) 2001-01-17
HU227822B1 (en) 2012-03-28
GB9417310D0 (en) 1994-10-19
AP9500754A0 (en) 1995-07-31
NO311297B1 (no) 2001-11-12
PL318319A1 (en) 1997-06-09
SI9520091A (sl) 1998-02-28
IL115013A0 (en) 1995-12-08
SK282922B6 (sk) 2003-01-09
IS4401A (is) 1996-12-19
FI113768B (fi) 2004-06-15
FI970800A (fi) 1997-02-26
UA45980C2 (uk) 2002-05-15
JPH09512283A (ja) 1997-12-09
MA23650A1 (fr) 1996-04-01
FI970800A0 (fi) 1997-02-26
DE69501620T2 (de) 1998-07-02
CA2198599A1 (en) 1996-03-07
ATE163182T1 (de) 1998-02-15
DK0776323T3 (da) 1998-03-30
PE41596A1 (es) 1996-10-12
KR100228952B1 (ko) 1999-11-01
EP0776323A1 (en) 1997-06-04
EG23822A (en) 2007-09-19
HRP950460B1 (en) 2000-02-29
CN1155886A (zh) 1997-07-30
YU49287B (sh) 2005-03-15
CN1066727C (zh) 2001-06-06
DZ1923A1 (fr) 2002-02-17
EP0776323B1 (en) 1998-02-11
ES2112650T3 (es) 1998-04-01
BG61840B1 (bg) 1998-07-31
GR3026475T3 (en) 1998-06-30
WO1996006842A1 (en) 1996-03-07
YU56995A (sh) 1998-07-10
SI9520091B (sl) 2004-10-31

Similar Documents

Publication Publication Date Title
OA10600A (en) Salts of an anti-migraine indole derivative
CN111269186A (zh) 激酶抑制剂及其盐的晶型
JP2008534470A (ja) Ｄｐｐ−ｉｖ阻害剤の新規な塩及び多形
JP2000506847A (ja) ４―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法
JP7338950B2 (ja) （ｓ）－［３，４－ジフルオロ－２－（２－フルオロ－４－ヨードフェニルアミノ）フェニル］［３－ヒドロキシ－３－（ピペリジン－２－イル」）アゼチジン－１－イル］－メタノンの結晶性フマル酸塩
US6534505B2 (en) Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same
CA2379572C (en) Polymorphic salt
JP2015514741A (ja) 結晶形態の（Ｓ）−４−アミノ−Ｎ−（１−（４−クロロフェニル）−３−ヒドロキシプロピル）−１−（７Ｈ−ピロロ［２，３−ｄ］−ピリミジン−４−イル）ピペリジン−４−カルボキサミド
HRP20010181A2 (en) N-substituted azabicycloheptane derivatives, production and use thereof